Can low‑dose naltrexone (LDN) and ivermectin be used to treat postural orthostatic tachycardia syndrome (POTS), Crohn’s disease, or gastroparesis?

Low-Dose Naltrexone and Ivermectin for POTS, Crohn's Disease, and Gastroparesis

Neither low-dose naltrexone nor ivermectin are recommended for treating POTS, Crohn's disease, or gastroparesis based on current evidence-based guidelines and FDA-approved indications.

Gastroparesis

The 2025 AGA Clinical Practice Guideline on gastroparesis 1 provides clear first-line treatment recommendations that do not include either low-dose naltrexone or ivermectin. The guideline recommends:

• Metoclopramide as the suggested first-line pharmacologic agent (conditional recommendation, low-quality evidence)
• Erythromycin at low doses (40-150 mg before meals) for prokinetic effects
• Domperidone and prucalopride are suggested against as first-line treatments but may be considered in shared decision-making

Key point: No evidence exists supporting LDN or ivermectin for gastroparesis. Ivermectin is FDA-approved only for parasitic infections (strongyloidiasis and onchocerciasis) 2, with no mechanism of action relevant to gastric motility.

Crohn's Disease

The 2020 ECCO Guidelines on therapeutics in Crohn's disease 3 establish evidence-based treatments including:

• 5-ASA compounds
• Corticosteroids (systemic and locally active like budesonide)
• Immunomodulators (azathioprine, mercaptopurine, methotrexate)
• Biologic therapies (anti-TNF, anti-integrins, anti-IL-12/23)

Low-dose naltrexone for Crohn's disease: While one small open-label pilot study from 2007 4 showed potential benefit (89% response rate, 67% remission rate with 4.5 mg/day), a 2018 Cochrane systematic review 5 concluded there is insufficient evidence to support LDN use. The Cochrane review found:

• Only two small studies (46 total participants)
• No statistically significant difference in clinical remission rates
• Overall quality of evidence rated as low due to serious imprecision
• The authors explicitly state: "Currently, there is insufficient evidence to allow any firm conclusions regarding the efficacy and safety of LDN"

Ivermectin has no role in Crohn's disease treatment and is not mentioned in IBD guidelines. Its FDA-approved indications are limited to parasitic infections 2.

Postural Orthostatic Tachycardia Syndrome (POTS)

Recent systematic reviews 6, 7 evaluating 21 randomized trials with 750 patients identify evidence-based treatments for POTS, which do not include LDN or ivermectin as recommended therapies. The evidence supports:

Non-pharmacological approaches (first-line):

• Compression garments
• Physical training/exercise programs
• Increased salt supplementation (typically 6-10 grams daily)
• Adequate fluid intake (2-3 liters daily)

Pharmacological options with trial evidence:

• Beta-blockers (propranolol)
• Ivabradine (significant effects shown)
• Midodrine (beneficial hemodynamic effects)
• Pyridostigmine (beneficial hemodynamic effects)

Low-dose naltrexone for POTS: The evidence is extremely limited:

• A 2023 case series 8 of only 6 patients showed 3/6 reported subjective improvement, but patient-reported outcome measures were inconsistent and contradictory
• A 2025 chart review 9 of 29 dysautonomia patients found no statistically significant changes in COMPASS-31 autonomic symptom scores after LDN treatment
• Only 24% showed documented pain improvement
• One 2018 case report 10 described dramatic response in a single patient receiving multiple simultaneous interventions (LDN + IVIg + antibiotics), making it impossible to attribute benefit to LDN alone

The evidence quality for LDN in POTS is extremely poor—limited to small case series without control groups, inconsistent outcome measures, and no randomized trials.

Ivermectin for POTS: One systematic review 6 mentions ivermectin was evaluated in trials, but provides no supporting evidence for its efficacy. Ivermectin's FDA-approved mechanism involves parasitic neuromuscular paralysis 2, with no established relevance to autonomic dysfunction.

Clinical Bottom Line

For all three conditions, use evidence-based guideline-recommended treatments:

1. Gastroparesis: Start with metoclopramide 5 mg before meals, with careful monitoring for adverse effects 1

2. Crohn's disease: Follow ECCO guidelines using established immunomodulators and biologics 3; LDN remains investigational with insufficient evidence 5

3. POTS: Begin with non-pharmacological measures (compression, exercise, salt/fluid loading), then consider beta-blockers, ivabradine, or midodrine based on individual hemodynamic profile 6, 7

Common pitfall: Patients may request these off-label therapies based on internet anecdotes or social media. The evidence does not support their use, and pursuing unproven treatments delays implementation of effective, guideline-based therapies that can improve morbidity and quality of life.